Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more
Enanta Pharmaceuticals Inc (ENTA) - Net Assets
Latest net assets as of December 2025: $126.59 Million USD
Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has net assets worth $126.59 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($329.50 Million) and total liabilities ($202.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $126.59 Million |
| % of Total Assets | 38.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -83.8% |
| 10-Year Change | -76.03% |
| Growth Volatility | 50.28 |
Enanta Pharmaceuticals Inc - Net Assets Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual net assets of Enanta Pharmaceuticals Inc from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $64.72 Million | -49.76% |
| 2024-09-30 | $128.81 Million | -40.57% |
| 2023-09-30 | $216.74 Million | -32.55% |
| 2022-09-30 | $321.33 Million | -19.55% |
| 2021-09-30 | $399.43 Million | -12.33% |
| 2020-09-30 | $455.58 Million | -1.49% |
| 2019-09-30 | $462.49 Million | +17.48% |
| 2018-09-30 | $393.68 Million | +30.50% |
| 2017-09-30 | $301.68 Million | +11.76% |
| 2016-09-30 | $269.94 Million | +14.30% |
| 2015-09-30 | $236.16 Million | +58.86% |
| 2014-09-30 | $148.65 Million | +34.57% |
| 2013-09-30 | $110.47 Million | +151.47% |
| 2012-09-30 | $43.93 Million | +133.29% |
| 2011-09-30 | $-131.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enanta Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27292500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $214.00K | 0.33% |
| Other Comprehensive Income | $-339.00K | -0.52% |
| Other Components | $469.77 Million | 725.89% |
| Total Equity | $64.72 Million | 100.00% |
Enanta Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningbo Ocean Shipping Co. Ltd. A
SHG:601022
|
$268.04 Million |
|
Synektik S.A.
WAR:SNT
|
$268.09 Million |
|
F.I.L.A. - Fabbrica Italiana Lapis ed Affini S.p.A
F:3S0
|
$268.19 Million |
|
SNT Motiv Co Ltd
KO:064960
|
$268.20 Million |
|
Qudian Inc
NYSE:QD
|
$267.92 Million |
|
Tianyang Hot Mel
SHG:603330
|
$267.91 Million |
|
GuangDong Leary New Material Technology Co. Ltd. A
SHG:688683
|
$267.87 Million |
|
Electrosteel Castings Limited
NSE:ELECTCAST
|
$267.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enanta Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 128,814,000 to 64,717,000, a change of -64,097,000 (-49.8%).
- Net loss of 81,889,000 reduced equity.
- Other comprehensive income decreased equity by 641,000.
- Other factors increased equity by 18,433,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-81.89 Million | -126.53% |
| Other Comprehensive Income | $-641.00K | -0.99% |
| Other Changes | $18.43 Million | +28.48% |
| Total Change | $- | -49.76% |
Book Value vs Market Value Analysis
This analysis compares Enanta Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-09-30 | $-10.30 | $13.27 | x |
| 2012-09-30 | $4.69 | $13.27 | x |
| 2013-09-30 | $11.29 | $13.27 | x |
| 2014-09-30 | $7.75 | $13.27 | x |
| 2015-09-30 | $12.24 | $13.27 | x |
| 2016-09-30 | $14.04 | $13.27 | x |
| 2017-09-30 | $15.54 | $13.27 | x |
| 2018-09-30 | $19.06 | $13.27 | x |
| 2019-09-30 | $22.06 | $13.27 | x |
| 2020-09-30 | $22.85 | $13.27 | x |
| 2021-09-30 | $19.80 | $13.27 | x |
| 2022-09-30 | $15.60 | $13.27 | x |
| 2023-09-30 | $10.34 | $13.27 | x |
| 2024-09-30 | $6.09 | $13.27 | x |
| 2025-09-30 | $3.03 | $13.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enanta Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -126.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -125.36%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 4.34x
- Recent ROE (-126.53%) is below the historical average (-12.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 55.66% | 1.60x | 0.00x | $36.51 Million |
| 2012 | 48.71% | 51.31% | 0.80x | 1.19x | $17.01 Million |
| 2013 | 8.71% | 30.03% | 0.27x | 1.06x | $-1.42 Million |
| 2014 | 23.17% | 72.14% | 0.31x | 1.05x | $19.57 Million |
| 2015 | 33.45% | 49.10% | 0.65x | 1.04x | $55.38 Million |
| 2016 | 8.03% | 24.55% | 0.31x | 1.04x | $-5.33 Million |
| 2017 | 5.87% | 17.23% | 0.31x | 1.08x | $-12.46 Million |
| 2018 | 18.28% | 34.82% | 0.50x | 1.05x | $32.59 Million |
| 2019 | 10.03% | 22.60% | 0.42x | 1.06x | $133.80K |
| 2020 | -7.94% | -29.53% | 0.25x | 1.08x | $-81.73 Million |
| 2021 | -19.78% | -81.38% | 0.22x | 1.10x | $-118.94 Million |
| 2022 | -37.89% | -141.31% | 0.23x | 1.18x | $-153.89 Million |
| 2023 | -61.74% | -168.95% | 0.17x | 2.13x | $-155.49 Million |
| 2024 | -90.09% | -171.58% | 0.18x | 2.92x | $-128.93 Million |
| 2025 | -126.53% | -125.36% | 0.23x | 4.34x | $-88.36 Million |
Industry Comparison
This section compares Enanta Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enanta Pharmaceuticals Inc (ENTA) | $126.59 Million | 0.00% | 1.60x | $268.04 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |